Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders the mobility of the patient and can have a substantial impact on quality of life. Therapeutic options for the treatment of RA have grown rapidly over the past two decades, having also expanded to encompass a number of highly successful biologics. Although clinically and commercially successful, there are a number of unmet needs in this market.
The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible summary of these clinical characteristics, provides detailed readouts of all late-stage clinical trial results for products in the RA market and Phase III pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population, are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease-of-use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
The rheumatoid arthritis market landscape is expected to change substantially with the advent of promising novel pipeline products.
Reasons to buy